CFDE Data Portal | Search SUGT1-DT

	Label	Description
	SUGT1-DT Gene (Entity type)	ENSG00000273723 - SUGT1 divergent transcript
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 3 V 5 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE82032 trametinib HCC1143 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE189859 GSE189861 IDH1 knockout 4 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE198930 prunetin AGS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

SUGT1-DT

ENSG00000273723 - SUGT1 divergent transcript

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

A Gene Set from LINCS

GSE135350 3 V 5 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 3 v 5 human up

A Gene Set from LINCS

GSE82032 trametinib HCC1143 3 v 1 human dn

A Gene Set from LINCS

GSE189859 GSE189861 IDH1 knockout 4 v 2 human dn

A Gene Set from LINCS

GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn

A Gene Set from LINCS

GSE198930 prunetin AGS 1 v 0 human dn

A Gene Set from LINCS

GSE77108 saha 5 v 2 human up

A Gene Set from LINCS

GSE203329 HCC knockout 2 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.